1 reports of this reaction
4.3% of all CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR reports
#6 most reported adverse reaction
BEDRIDDEN is the #6 most commonly reported adverse reaction for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, manufactured by ARMY AND AIR FORCE EXCHANGE SERVICE. There are 1 FDA adverse event reports linking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR to BEDRIDDEN. This represents approximately 4.3% of all 23 adverse event reports for this drug.
Patients taking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR who experience bedridden should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BEDRIDDEN is moderately reported among CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR users, representing a notable but not dominant share of adverse events.
In addition to bedridden, the following adverse reactions have been reported for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR:
BEDRIDDEN has been reported as an adverse event in 1 FDA reports for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
BEDRIDDEN accounts for approximately 4.3% of all adverse event reports for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, making it a notable side effect.
If you experience bedridden while taking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.